{"success":true,"data":{"pressRelease":{"id":"136434","rtpr_id":"nGNX7JdD60-20260904","ticker":"ORIC","exchange":"NASDAQ","all_tickers":["ORIC"],"title":"ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)","author":"Globe Newswire","published_at":"2026-09-04T20:30:00.095Z","article_body":"SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Sept. 04, 2026 (GLOBE NEWSWIRE) --\nORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company\nfocused on developing treatments that address mechanisms of therapeutic\nresistance, today announced that on September 1, 2026 (the “Grant Date”),\nORIC granted a total of 39,200 non-qualified stock options and 6,400\nrestricted stock units to two new non-executive employees who began their\nemployment with ORIC in August 2026.\n\nThese inducement grants were granted pursuant to the ORIC Pharmaceuticals,\nInc. 2022 Inducement Equity Incentive Plan, subject to recipient’s continued\nemployment or service through each applicable vesting date. The stock options\nhave an exercise price equal to the closing price of ORIC’s common stock on\nthe Grant Date. Twenty-five percent (25%) of the shares subject to the stock\noptions will vest on the one (1) year anniversary of the Grant Date, with one\nthirty-sixth (1/36(th)) of the remaining shares vesting each one-month period\nthereafter. One-third (1/3(rd)) of the restricted stock units will vest on\neach of the first three anniversaries of the Grant Date. The inducement grants\nare subject to the terms and conditions of the applicable stock option and\nrestricted stock unit agreements and the ORIC Pharmaceuticals, Inc. 2022\nInducement Equity Incentive Plan.\n\nThe inducement grants were approved by ORIC’s Compensation Committee of the\nBoard of Directors, as required by Nasdaq Rule 5635(c)(4), and were granted as\na material inducement to employment in accordance with Nasdaq Rule 5635(c)(4).\n\nAbout ORIC Pharmaceuticals, Inc.\n\nORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated\nto improving patients’ lives by Overcoming Resistance In Cancer. ORIC’s\nclinical stage product candidates include (1) rinzimetostat, an allosteric\ninhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit,\nbeing developed for prostate cancer, and (2) enozertinib, a brain penetrant\ninhibitor targeting EGFR exon 20 insertion and EGFR atypical mutations, being\ndeveloped for NSCLC. ORIC has offices in South San Francisco and San Diego,\nCalifornia. For more information, please go to www.oricpharma.com, and follow\nus on X\n(https://www.globenewswire.com/Tracker?data=lQNi_92OHgUTuwT0oa1GUP24OWPXez2zY0Zi5aWLIeOBVZ0WCvfRMUJ0xhLFowPUkdFsaJLd-jyBDIQ-pZCFLw==)\nor LinkedIn\n(https://www.globenewswire.com/Tracker?data=Mb_zhPEgYNnvsXRqJoD5UzvSRF8f2HsK1UuCsMQ1MD3HRwuFQfeQO3zDyLNISfx_s9wU59zF5hyLsHgz4fivPkuB-WBPw7UjkN2uxpzL6yPB5YeTGHhcUunIwedix1fX).\n\nCautionary Note Regarding Forward-Looking Statements\nThis press release contains forward-looking statements as that term is defined\nin Section 27A of the Securities Act of 1933 and Section 21E of the Securities\nExchange Act of 1934. Statements in this press release that are not purely\nhistorical are forward-looking statements. Such forward-looking statements\ninclude, among other things, statements regarding the vesting of the\ninducement grants; target indications for ORIC’s product candidates; the\npotential advantages of ORIC’s product candidates; and plans underlying\nORIC’s clinical trials and development. Words such as “believes,”\n“anticipates,” “plans,” “expects,” “intends,” “will,”\n“goal,” “potential” and similar expressions are intended to identify\nforward-looking statements. The forward-looking statements contained herein\nare based upon ORIC’s current expectations and involve assumptions that may\nnever materialize or may prove to be incorrect. Actual results could differ\nmaterially from those projected in any forward-looking statements due to\nnumerous risks and uncertainties, including but not limited to: risks\nassociated with the process of discovering, developing and commercializing\ndrugs that are safe and effective for use as human therapeutics and operating\nas an early clinical stage company; ORIC’s ability to develop, initiate or\ncomplete preclinical studies and clinical trials for, obtain approvals for and\ncommercialize any of its product candidates; changes in ORIC’s plans to\ndevelop and commercialize its product candidates; the potential for clinical\ntrials of ORIC’s product candidates to differ from preclinical, initial,\ninterim, preliminary or expected results; negative impacts of health\nemergencies, economic instability or international conflicts on ORIC’s\noperations, including clinical trials; the risk of the occurrence of any\nevent, change or other circumstance that could give rise to the termination of\nORIC’s license and collaboration agreements; the potential market for our\nproduct candidates, and the progress and success of competing therapeutics\ncurrently available or in development; ORIC’s ability to raise any\nadditional funding it will need to continue to pursue its business and product\ndevelopment plans; regulatory developments in the United States and foreign\ncountries; ORIC’s reliance on third parties, including contract\nmanufacturers and contract research organizations; ORIC’s ability to obtain\nand maintain intellectual property protection for its product candidates; the\nloss of key scientific or management personnel; competition in the industry in\nwhich ORIC operates; general economic and market conditions; and other risks.\nInformation regarding the foregoing and additional risks may be found in the\nsection entitled “Risk Factors” in ORIC’s Quarterly Report on Form 10-Q\nfiled with the Securities and Exchange Commission (the “SEC”) on August 3,\n2026, and ORIC’s future reports to be filed with the SEC. These\nforward-looking statements are made as of the date of this press release, and\nORIC assumes no obligation to update the forward-looking statements, or to\nupdate the reasons why actual results could differ from those projected in the\nforward-looking statements, except as required by law.\n\nContact:\nDominic Piscitelli, Chief Financial Officer\ndominic.piscitelli@oricpharma.com \ninfo@oricpharma.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/acbc0ad2-7a44-4ee7-b729-ab92d57ffafb)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX7JdD60-20260904","title":"ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)","author":"Globe Newswire","ticker":"ORIC","created":"2026-09-04T20:30:00.095Z","tickers":["ORIC"],"exchange":"NASDAQ","article_body":"SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Sept. 04, 2026 (GLOBE NEWSWIRE) --\nORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company\nfocused on developing treatments that address mechanisms of therapeutic\nresistance, today announced that on September 1, 2026 (the “Grant Date”),\nORIC granted a total of 39,200 non-qualified stock options and 6,400\nrestricted stock units to two new non-executive employees who began their\nemployment with ORIC in August 2026.\n\nThese inducement grants were granted pursuant to the ORIC Pharmaceuticals,\nInc. 2022 Inducement Equity Incentive Plan, subject to recipient’s continued\nemployment or service through each applicable vesting date. The stock options\nhave an exercise price equal to the closing price of ORIC’s common stock on\nthe Grant Date. Twenty-five percent (25%) of the shares subject to the stock\noptions will vest on the one (1) year anniversary of the Grant Date, with one\nthirty-sixth (1/36(th)) of the remaining shares vesting each one-month period\nthereafter. One-third (1/3(rd)) of the restricted stock units will vest on\neach of the first three anniversaries of the Grant Date. The inducement grants\nare subject to the terms and conditions of the applicable stock option and\nrestricted stock unit agreements and the ORIC Pharmaceuticals, Inc. 2022\nInducement Equity Incentive Plan.\n\nThe inducement grants were approved by ORIC’s Compensation Committee of the\nBoard of Directors, as required by Nasdaq Rule 5635(c)(4), and were granted as\na material inducement to employment in accordance with Nasdaq Rule 5635(c)(4).\n\nAbout ORIC Pharmaceuticals, Inc.\n\nORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated\nto improving patients’ lives by Overcoming Resistance In Cancer. ORIC’s\nclinical stage product candidates include (1) rinzimetostat, an allosteric\ninhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit,\nbeing developed for prostate cancer, and (2) enozertinib, a brain penetrant\ninhibitor targeting EGFR exon 20 insertion and EGFR atypical mutations, being\ndeveloped for NSCLC. ORIC has offices in South San Francisco and San Diego,\nCalifornia. For more information, please go to www.oricpharma.com, and follow\nus on X\n(https://www.globenewswire.com/Tracker?data=lQNi_92OHgUTuwT0oa1GUP24OWPXez2zY0Zi5aWLIeOBVZ0WCvfRMUJ0xhLFowPUkdFsaJLd-jyBDIQ-pZCFLw==)\nor LinkedIn\n(https://www.globenewswire.com/Tracker?data=Mb_zhPEgYNnvsXRqJoD5UzvSRF8f2HsK1UuCsMQ1MD3HRwuFQfeQO3zDyLNISfx_s9wU59zF5hyLsHgz4fivPkuB-WBPw7UjkN2uxpzL6yPB5YeTGHhcUunIwedix1fX).\n\nCautionary Note Regarding Forward-Looking Statements\nThis press release contains forward-looking statements as that term is defined\nin Section 27A of the Securities Act of 1933 and Section 21E of the Securities\nExchange Act of 1934. Statements in this press release that are not purely\nhistorical are forward-looking statements. Such forward-looking statements\ninclude, among other things, statements regarding the vesting of the\ninducement grants; target indications for ORIC’s product candidates; the\npotential advantages of ORIC’s product candidates; and plans underlying\nORIC’s clinical trials and development. Words such as “believes,”\n“anticipates,” “plans,” “expects,” “intends,” “will,”\n“goal,” “potential” and similar expressions are intended to identify\nforward-looking statements. The forward-looking statements contained herein\nare based upon ORIC’s current expectations and involve assumptions that may\nnever materialize or may prove to be incorrect. Actual results could differ\nmaterially from those projected in any forward-looking statements due to\nnumerous risks and uncertainties, including but not limited to: risks\nassociated with the process of discovering, developing and commercializing\ndrugs that are safe and effective for use as human therapeutics and operating\nas an early clinical stage company; ORIC’s ability to develop, initiate or\ncomplete preclinical studies and clinical trials for, obtain approvals for and\ncommercialize any of its product candidates; changes in ORIC’s plans to\ndevelop and commercialize its product candidates; the potential for clinical\ntrials of ORIC’s product candidates to differ from preclinical, initial,\ninterim, preliminary or expected results; negative impacts of health\nemergencies, economic instability or international conflicts on ORIC’s\noperations, including clinical trials; the risk of the occurrence of any\nevent, change or other circumstance that could give rise to the termination of\nORIC’s license and collaboration agreements; the potential market for our\nproduct candidates, and the progress and success of competing therapeutics\ncurrently available or in development; ORIC’s ability to raise any\nadditional funding it will need to continue to pursue its business and product\ndevelopment plans; regulatory developments in the United States and foreign\ncountries; ORIC’s reliance on third parties, including contract\nmanufacturers and contract research organizations; ORIC’s ability to obtain\nand maintain intellectual property protection for its product candidates; the\nloss of key scientific or management personnel; competition in the industry in\nwhich ORIC operates; general economic and market conditions; and other risks.\nInformation regarding the foregoing and additional risks may be found in the\nsection entitled “Risk Factors” in ORIC’s Quarterly Report on Form 10-Q\nfiled with the Securities and Exchange Commission (the “SEC”) on August 3,\n2026, and ORIC’s future reports to be filed with the SEC. These\nforward-looking statements are made as of the date of this press release, and\nORIC assumes no obligation to update the forward-looking statements, or to\nupdate the reasons why actual results could differ from those projected in the\nforward-looking statements, except as required by law.\n\nContact:\nDominic Piscitelli, Chief Financial Officer\ndominic.piscitelli@oricpharma.com \ninfo@oricpharma.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/acbc0ad2-7a44-4ee7-b729-ab92d57ffafb)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-09-04T20:30:00.148031251Z","server_sent_at_ms":1788553800148},"received_at":"2026-09-04T20:30:00.206Z","source_url":null},"analysis":{"id":"125310","press_release_id":"136434","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"other","narrative":"ORIC Pharmaceuticals granted 39,200 non-qualified stock options and 6,400 restricted stock units to two new non-executive employees as employment inducement grants on September 1, 2026, under its 2022 Inducement Equity Incentive Plan as permitted by Nasdaq Rule 5635(c)(4).\n\nVesting is standard: options vest 25% on the one-year anniversary with 1/36 of the remainder vesting monthly thereafter, and RSUs vest in thirds on the first three anniversaries; the option exercise price equals the closing price on the grant date.\n\nThis is a routine, immaterial equity compensation disclosure with no information content regarding ORIC's clinical programs, which include rinzimetostat in prostate cancer and enozertinib in NSCLC.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Routine inducement-grant filing with no signal content -- suppress."},"keyFigures":{"customDimensions":{"grant_date":"2026-09-01","recipients":2,"rsus_granted":6400,"options_granted":39200}},"namedEntities":{"people":[{"name":"Dominic Piscitelli","role":"Chief Financial Officer"}],"products":["rinzimetostat","enozertinib"],"companies":[{"name":"ORIC Pharmaceuticals, Inc.","ticker":"ORIC","relationship":"filer"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Routine Nasdaq Rule 5635(c)(4) inducement equity grants totaling only 45,600 option/RSU equivalents to two new non-executive hires. Boilerplate compensation disclosure with no bearing on the clinical pipeline, financials, or valuation."},"tickerRelevance":{"others":[],"primary":"ORIC"},"globalImportance":8,"audienceRelevance":15,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap clinical-stage biotech","eventGravity":"routine-inducement-grant","issuerAuthored":true,"dilutiveMagnitude":"immaterial (~45.6k equity units)"}},"event_type":"other","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"ORIC Pharmaceuticals granted 39,200 non-qualified stock options and 6,400 restricted stock units to two new non-executive employees as employment inducement grants on September 1, 2026, under its 2022 Inducement Equity Incentive Plan as permitted by Nasdaq Rule 5635(c)(4).\n\nVesting is standard: options vest 25% on the one-year anniversary with 1/36 of the remainder vesting monthly thereafter, and RSUs vest in thirds on the first three anniversaries; the option exercise price equals the closing price on the grant date.\n\nThis is a routine, immaterial equity compensation disclosure with no information content regarding ORIC's clinical programs, which include rinzimetostat in prostate cancer and enozertinib in NSCLC.","key_figures":{"customDimensions":{"grant_date":"2026-09-01","recipients":2,"rsus_granted":6400,"options_granted":39200}},"named_entities":{"people":[{"name":"Dominic Piscitelli","role":"Chief Financial Officer"}],"products":["rinzimetostat","enozertinib"],"companies":[{"name":"ORIC Pharmaceuticals, Inc.","ticker":"ORIC","relationship":"filer"}],"dollarAmounts":[]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-04T20:30:41.477Z","global_importance":8,"audience_relevance":15,"importance_components":{"tickerTier":"small-cap clinical-stage biotech","eventGravity":"routine-inducement-grant","issuerAuthored":true,"dilutiveMagnitude":"immaterial (~45.6k equity units)"}},"durationMs":41265,"modelName":"glm-4.7"}}